Obatala Sciences Closes $3 Million Series A Funding Round Co-Led By Être Venture Capital And Ochsner Health

Oct 13, 2022•about 3 years ago

Amount Raised

$3 Million

Round Type

series a

New OrleansBiotechnologyHealth Care

Description

Obatala Sciences, a New Orleans biotechnology company recognized for speeding up therapies for obesity, diabetes, and cancer across diverse populations, today announced the closing of a $3 million Series A finance round co-led by être Venture Capital and Ochsner Lafayette General Healthcare Innovation Fund II and joined by Benson Capital Partners, Elevate Capital Fund, and The Hackett-Robertson-Tobe Group.

Company Information

Company

Obatala Sciences

Location

New Orleans, Louisiana, United States

About

Obatala Sciences offers contract research services and research products to laboratories in industry and in academia. Our clients include major pharmaceutical companies, US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Our areas of expertise include obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. ObaCell™, a unique fat tissue model, is a great tool for disease modeling and drug screening. Obatala Sciences can provide data in various areas depending on your interest including proteomics, genomics, functionality, and adipokine secretion. We also have the capability of forming white or brown fat tissue upon request.

Related People

2 contacts

Obatala Sciences Closes $3 Million Series A Funding Round Co-Led By Être Venture Capital And Ochsner Health

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information